Plant Name: Santalum album
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GRM1; GRM5; GRM3; GRM2; GRM8; GRM4; | |
| ADORA3; GPBAR1; | |
| TSHR; | |
| PLA2G1B; TDP1; BLM; GLA; FAAH; RECQL; TERT; PKM; GLO1; HSD17B1; AKR1B1; HSD17B10; ALOX15; AKR1B10; ALDH1A1; GFER; ALOX12; NOX4; USP2; TNKS; PARP1; TNKS2; APEX1; POLB; CD38; | |
| PTPN1; CDC25B; PTPN2; | |
| ACHE; GAA; | |
| GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; GRIK2; | |
| CFTR; | |
| CSNK2A1; SYK; FLT3; GSK3B; MAPK1; PIM1; CDK6; | |
| CA12; CA7; CA4; CA2; | |
| AR; | |
| PPARD; PPARA; PPARG; | |
| NR1H4; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS2; XDH; | |
| MMP12; MMP2; MMP9; | |
| TLR2; | |
| HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| SLC1A1; | |
| LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; THPO; HTT; RAB9A; NPC1; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Ionotropic glutamate receptor | GRIK2 | Glutamate receptor ionotropic kainate 2 | Q13002 | CHEMBL3683 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GRM5 | Metabotropic glutamate receptor 5 | P41594 | CHEMBL3227 |
| Small molecule receptor (family C GPCR) | GRM3 | Metabotropic glutamate receptor 3 | Q14832 | CHEMBL2888 |
| Small molecule receptor (family C GPCR) | GRM2 | Metabotropic glutamate receptor 2 | Q14416 | CHEMBL5137 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Small molecule receptor (family C GPCR) | GRM4 | Metabotropic glutamate receptor 4 | Q14833 | CHEMBL2736 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0023052; signaling | GO:0051966; regulation of synaptic transmission, glutamatergic | 4.920E-13 | 3.061E-10 | GRIK1, GRIK2, GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, PTGS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.540E-12 | 8.382E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.113E-11 | 8.366E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.346E-11 | 1.526E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, XDH |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 5.247E-11 | 1.758E-08 | APP, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.794E-10 | 5.661E-08 | CA2, CA7, CFTR, HIF1A, HTT, MAPK1, NPC1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 4.515E-10 | 1.311E-07 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.729E-10 | 2.318E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| CC | GO:0044456; synapse part | GO:0042734; presynaptic membrane | 1.129E-09 | 2.794E-07 | GRIK2, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.320E-09 | 3.160E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.652E-09 | 3.775E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.474E-09 | 5.497E-07 | ABCG2, ACHE, APP, BLM, CD38, CSNK2A1, ESR1, ESR2, FLT3, GLA, GRIK2, GRIK5, HTT, MAPK1, MAPT, MMP9, NFKB1, PARP1, PKM, PPARG, PTGS2, RAB9A, SMN1, SMN2, TERT, TP53, TTR, USP2, XDH |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.264E-09 | 6.705E-07 | CA2, CA7, CD38, CDK6, CFTR, HIF1A, HTT, MAPK1, NPC1, NR1H4, PARP1, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 3.506E-09 | 7.136E-07 | GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.441E-09 | 1.189E-06 | AR, BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, GLO1, MMP12, MMP2, MMP9, NR1H4, PARP1, PPARA, PPARD, PPARG, PTPN1, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.735E-08 | 9.281E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.443E-07 | 1.827E-05 | CA2, CA7, CFTR, GRM5 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.933E-07 | 3.344E-05 | ADORA3, AR, ESR1, ESR2, FLT3, GPBAR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, NPC1, NR1H4, PPARA, PPARD, PPARG, TLR2, TSHR |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.318E-07 | 3.686E-05 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.375E-07 | 3.712E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.375E-07 | 3.712E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.529E-07 | 5.653E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.195E-07 | 8.854E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.221E-06 | 1.128E-04 | ALOX12, ALOX15, ALOX5, PTGS2 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.356E-06 | 1.245E-04 | AKR1B1, GRIK2, GRIK3, HIF1A, MAPK1, MAPT |
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 1.616E-06 | 1.450E-04 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 2.238E-06 | 1.934E-04 | AKR1B1, APEX1, BLM, CDK6, CFTR, CYP1B1, MAPK1, NFKB1, PTGS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.391E-06 | 2.042E-04 | CYP19A1, NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.267E-06 | 2.645E-04 | CA12, CA2, CA4, CA7, CFTR |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.817E-06 | 3.056E-04 | AR, ESR1, ESR2, NR1H4, PIM1, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.936E-06 | 3.128E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.409E-06 | 4.133E-04 | AR, ESR1, ESR2, NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.186E-06 | 5.942E-04 | FABP2, FABP3, FABP4, FABP5 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 8.238E-06 | 5.944E-04 | AKR1B1, APP, CA2, CDK6, GRIA2, GRIA4, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM5, HIF1A, HTT, MAPK1, MAPT, PKM, PTGS2, SMN1, SMN2, TLR2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.127E-05 | 7.813E-04 | APP, GRM5, GSK3B, PARP1 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 1.139E-05 | 7.826E-04 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 1.731E-05 | 1.135E-03 | AR, CDK6, CFTR, ESR1, FLT3, NFKB1, NPC1, NR1H4, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.765E-05 | 1.151E-03 | HIF1A, LMNA, PPARD, PTGS2, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.813E-05 | 1.178E-03 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 1.966E-05 | 1.263E-03 | AR, CA2, CD38, FLT3, NPC1, PARP1, PTGS2, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.101E-05 | 1.333E-03 | AR, ESR1, ESR2, NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 2.112E-05 | 1.333E-03 | ACHE, CD38, GRIK2, GRIK3, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 2.188E-05 | 1.373E-03 | AKR1B1, APEX1, CYP1B1, MAPK1, MMP9, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 2.221E-05 | 1.382E-03 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 2.221E-05 | 1.382E-03 | GSK3B, HTT, MAPT |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 2.464E-05 | 1.524E-03 | MAPK1, MAPT, PPARA, PPARG, PTPN1, SYK, TP53 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 2.642E-05 | 1.621E-03 | FABP3, PLA2G1B, PPARA, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.707E-05 | 1.624E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.707E-05 | 1.624E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.707E-05 | 1.624E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.707E-05 | 1.624E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0001641; group II metabotropic glutamate receptor activity | 2.707E-05 | 1.624E-03 | GRM2, GRM3 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 3.125E-05 | 1.844E-03 | GRIK2, GRIK3, GRIK5, MAPK1, SMN1, SMN2 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 3.270E-05 | 1.914E-03 | BLM, GSK3B, HIF1A, HTT, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.647E-05 | 2.079E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0032501; multicellular organismal process | GO:0051240; positive regulation of multicellular organismal process | 3.845E-05 | 2.152E-03 | ALOX12, APP, AR, CA2, CD38, CYP1B1, HIF1A, MAPT, MMP12, MMP9, NFKB1, NR1H4, PARP1, PIM1, PPARG, PTGS2, SLC1A1, SYK, TERT, THPO, TLR2 |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 4.534E-05 | 2.478E-03 | MMP2, MMP9, PPARD, PTGS2 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 4.547E-05 | 2.478E-03 | AKR1B1, AKR1B10, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AR, BLM, CA2, CA7, CDC25B, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GFER, GLO1, GSK3B, HIF1A, HSD17B1, HTT, LMNA, MAPK1, MAPT, NFKB1, PIM1, PKM, PLA2G1B, PPARG, PTPN1, PTPN2, RAB9A, SMN1, SMN2, SYK, TNKS, TNKS2, TP53, XDH |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.804E-05 | 2.595E-03 | AKR1B1, ALOX5, APEX1, AR, BLM, CDC25B, CDK6, CSNK2A1, ESR1, ESR2, FABP5, GSK3B, HIF1A, HTT, LMNA, MAPK1, NFKB1, NR1H4, PARP1, PIM1, POLB, PPARA, PPARD, PPARG, PTPN2, RECQL, SMN1, SMN2, TERT, TNKS, TP53, USP2 |
| BP | GO:0065007; biological regulation | GO:0043086; negative regulation of catalytic activity | 5.604E-05 | 2.969E-03 | APP, CSNK2A1, FABP4, GLA, GRM2, GRM3, GSK3B, MAPT, MMP9, NFKB1, PPARG, PTGS2, PTPN1, PTPN2, TP53 |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 5.703E-05 | 3.007E-03 | APP, CFTR, CYP19A1, CYP1B1, NPC1, PPARD |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 6.032E-05 | 3.165E-03 | TERT, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 6.233E-05 | 3.232E-03 | FABP3, NR1H4, PPARG, PTGS2, TLR2 |
| BP | GO:0007610; behavior | GO:0007612; learning | 7.990E-05 | 3.853E-03 | APP, GRM5, HIF1A, HTT, PTGS2, TLR2 |
| BP | Unclassified; | GO:0099566; regulation of postsynaptic cytosolic calcium ion concentration | 8.094E-05 | 3.853E-03 | GRM1, GRM5 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 8.094E-05 | 3.853E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 8.094E-05 | 3.853E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.094E-05 | 3.853E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 8.094E-05 | 3.853E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 8.094E-05 | 3.853E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 8.094E-05 | 3.853E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 8.094E-05 | 3.853E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 8.094E-05 | 3.853E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0099583; neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration | 8.094E-05 | 3.853E-03 | GRM1, GRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 8.094E-05 | 3.853E-03 | GPBAR1, NR1H4 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 8.105E-05 | 3.853E-03 | ADORA3, FLT3, GPBAR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, NPC1, PPARG, TSHR |
| CC | GO:0032991; macromolecular complex | GO:0032983; kainate selective glutamate receptor complex | 8.094E-05 | 3.853E-03 | GRIK2, GRIK5 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 8.140E-05 | 3.862E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 8.527E-05 | 4.019E-03 | ABCG2, ACHE, AR, BLM, FLT3, GLA, GRIK2, HIF1A, MAPT, NFKB1, PPARD, PPARG, PTGS2, TERT, TLR2, TP53, TTR, XDH |
| BP | GO:0008283; cell proliferation | GO:0048145; regulation of fibroblast proliferation | 8.809E-05 | 4.143E-03 | CDK6, ESR1, PLA2G1B, PPARG, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 8.946E-05 | 4.162E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 8.946E-05 | 4.162E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.054E-04 | 4.823E-03 | GRM1, GRM4, MAPK1, PLA2G1B, PTPN1, SYK |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.093E-04 | 4.949E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 1.213E-04 | 5.366E-03 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM3 |
| BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 1.348E-04 | 5.859E-03 | APEX1, APP, CFTR, NOX4 |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 1.483E-04 | 6.343E-03 | ESR1, PPARA, TERT |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 1.583E-04 | 6.744E-03 | APP, CD38, GRIK2, GRM5, MAPK1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.613E-04 | 6.746E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.613E-04 | 6.746E-03 | PTPN1, PTPN2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.613E-04 | 6.746E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.613E-04 | 6.746E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.613E-04 | 6.746E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 1.613E-04 | 6.746E-03 | GRIA2, GRIA4 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.613E-04 | 6.746E-03 | ALDH1A1, AR |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.635E-04 | 6.820E-03 | APP, MAPK1, PARP1, PTGS2, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.822E-04 | 7.528E-03 | NOX4, PARP1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 1.822E-04 | 7.528E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.883E-04 | 7.737E-03 | GRIK5, HIF1A, NOX4, NR1H4, PPARG, PTPN2 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 1.895E-04 | 7.770E-03 | ACHE, APEX1, CSNK2A1, FLT3, MAPT, MMP12, MMP9, PIM1, PKM, PPARA, PTPN1, PTPN2, SYK, TLR2, TSHR |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 1.924E-04 | 7.877E-03 | ALOX12, APP, CD38, CDK6, GSK3B, HIF1A, LMNA, NFKB1, NR1H4, PPARD, PPARG, PTGS2, PTPN2, TERT, TLR2, XDH |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.988E-04 | 8.012E-03 | HIF1A, TERT, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.988E-04 | 8.012E-03 | MMP2, MMP9, TERT |
| BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 2.155E-04 | 8.577E-03 | ALOX5, FABP5, GAA, GLA, MAPK1, MMP9, NFKB1, PKM, TLR2, TTR |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.277E-04 | 8.984E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.360E-04 | 9.243E-03 | HIF1A, MMP12, MMP2, MMP9, PLA2G1B |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 2.364E-04 | 9.243E-03 | APP, AR, CA2, HIF1A, MAPT, NFKB1, PARP1, PPARD, PPARG, PTGS2, SYK, TERT, THPO, TLR2 |
| BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 2.466E-04 | 9.589E-03 | CYP19A1, NFKB1, PPARA, PPARG, SYK |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 2.593E-04 | 9.940E-03 | CYP1A1, CYP1A2, PPARG |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.575E-04 | 9.940E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 3.087E-15 | 3.955E-12 | GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 5.702E-16 | 1.083E-13 | GRIA2; GRIK5; SLC1A1; GRIK3; GRIK1; GRIK2; GRM1; GRM3; GRM2; GRM5; GRM4; GRM8; MAPK1; GRIA4 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.204E-10 | 1.144E-08 | GRIA2; GRIK5; GRIK3; GRIK1; GRIK2; TSHR; GRM1; GRM3; GRM2; GRM5; GRM4; ADORA3; GRM8; GRIA4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.529E-10 | 1.602E-08 | CYP2C9; APP; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.658E-08 | 1.010E-06 | CYP2C9; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.027E-07 | 2.789E-06 | GSK3B; FLT3; MMP2; PTGS2; HIF1A; MMP9; NFKB1; AR; CDK6; MAPK1; PPARG; TP53; PPARD |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.171E-09 | 2.931E-07 | CYP2C9; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.666E-08 | 1.794E-06 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.895E-07 | 4.000E-06 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.945E-07 | 1.161E-05 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; CYP2C9; PKM; AKR1B10; HSD17B1; ALOX5; CYP1A2; ALDH1A1; CYP1A1; CD38; XDH |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 6.828E-07 | 1.161E-05 | GRM3; GRM2; GRM5; GRM4; SYK; GRM8; MAPK1; GRM1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.892E-07 | 4.000E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 7.918E-07 | 1.161E-05 | GRIA2; FAAH; GRM5; MAPK1; PTGS2; GRM1; GRIA4 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.672E-07 | 8.877E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.617E-06 | 2.925E-05 | ABCC1; CDK6; PIM1; CYP1B1; MAPK1; PTGS2; TP53; MMP9; NFKB1; CDC25B |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.323E-06 | 1.756E-05 | CYP2C9; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.849E-06 | 2.195E-05 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 5.818E-06 | 5.818E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1; TLR2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.095E-05 | 9.905E-05 | MMP2; MAPK1; ESR1; MMP9; ESR2; GRM1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.011E-05 | 9.600E-05 | FLT3; PIM1; MAPK1; NFKB1; PPARD |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 4.752E-06 | 5.016E-05 | GRM3; GRIA2; GRM2; MAOA; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.687E-05 | 4.869E-04 | MMP2; MAPK1; TP53; HIF1A; ESR1; MMP9; TLR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.240E-05 | 1.773E-04 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.784E-05 | 4.445E-04 | GRIA2; MAPK1; PPARA; CFTR; NFKB1; TSHR; GRIA4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.181E-05 | 2.324E-04 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.175E-05 | 5.010E-04 | POLB; CDK6; PKM; SYK; MAPK1; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.931E-05 | 1.595E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.786E-05 | 5.635E-04 | CDK6; MAPK1; TP53; MMP9; NFKB1; TLR2 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.972E-05 | 2.258E-04 | CA2; NR1H4; CYP3A4; CFTR; ABCG2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.818E-05 | 5.235E-04 | GSK3B; AR; MAPK1; TP53; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.087E-04 | 6.072E-04 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.312E-04 | 1.736E-03 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 5.634E-04 | 2.420E-03 | GSK3B; SYK; CSNK2A1; CD38; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.579E-04 | 1.744E-03 | ABCC1; ADORA3; MAPK1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.233E-04 | 2.924E-03 | PARP1; LMNA; MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.732E-04 | 2.420E-03 | GSK3B; MAPK1; PPARA; TP53; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.374E-05 | 3.647E-04 | MMP2; MAPK1; MMP9; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.473E-04 | 1.736E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.869E-05 | 3.426E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 3.473E-04 | 1.736E-03 | GRIA2; GRM5; MAPK1; GRM1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.518E-05 | 1.311E-04 | AKR1B10; GAA; AKR1B1; GLA |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.722E-03 | 6.172E-03 | GSK3B; CDK6; SYK; MAPK1; TP53; NFKB1; TLR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.105E-04 | 2.256E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 5.105E-04 | 2.256E-03 | GSK3B; SYK; MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.105E-04 | 2.256E-03 | MAPK1; PTGS2; NFKB1; TLR2 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.719E-03 | 6.172E-03 | MMP2; PIM1; MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.630E-03 | 6.074E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.204E-03 | 7.756E-03 | FLT3; PPARG; TP53; MMP9; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.473E-04 | 3.750E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.272E-03 | 7.829E-03 | PTPN1; GSK3B; PPARA; NFKB1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.426E-03 | 5.419E-03 | CA2; PLA2G1B; CD38; CFTR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.349E-03 | 7.829E-03 | MAPK1; PTGS2; MMP9; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.216E-03 | 1.002E-02 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.027E-03 | 9.587E-03 | ALOX5; MAPK1; NFKB1; TLR2 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 4.164E-03 | 1.199E-02 | GRIA2; GSK3B; MAOA; GRIA4 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 3.617E-03 | 1.074E-02 | GSK3B; CDK6; TP53; CDC25B |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.518E-03 | 1.262E-02 | SYK; MAPK1; PPARG; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 9.519E-03 | 2.444E-02 | MAPK1; MAPT; TP53; NFKB1; CDC25B |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 5.843E-03 | 1.564E-02 | GSK3B; CSNK2A1; TP53; PPARD |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 9.979E-03 | 2.482E-02 | POLB; GSK3B; TERT; TP53; NFKB1 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.386E-06 | 1.756E-05 | CA12; CA2; CA4; CA7 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.269E-02 | 2.976E-02 | SYK; MAPK1; NFKB1; TLR2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.444E-02 | 3.305E-02 | CSNK2A1; TP53; NFKB1; TLR2 |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 1.661E-02 | 3.587E-02 | GRM5; HTT; PPARG; TP53 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.202E-02 | 2.892E-02 | PPARG; TP53; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.536E-02 | 3.474E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 1.237E-02 | 2.938E-02 | GRIA2; MAPK1; GRIA4 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.854E-03 | 9.190E-03 | FABP4; PTGS2; TSHR |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.657E-02 | 3.587E-02 | MAPK1; NFKB1; TLR2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.576E-02 | 3.481E-02 | GSK3B; MAPK1; NFKB1 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.006E-02 | 2.482E-02 | THPO; FLT3; CD38 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.576E-02 | 3.481E-02 | MAPK1; NFKB1; TLR2 |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 2.446E-02 | 4.952E-02 | NPC1; GAA; GLA |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 5.572E-03 | 1.512E-02 | CDK6; MAPK1; TP53 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.006E-02 | 2.482E-02 | GRM5; MAPK1; GRM1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.309E-03 | 7.829E-03 | GSK3B; MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.854E-03 | 9.190E-03 | CDK6; MAPK1; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.352E-03 | 1.234E-02 | CDK6; MAPK1; TP53 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 3.472E-03 | 1.047E-02 | GRIA2; MAPK1; GRM1 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 4.739E-03 | 1.305E-02 | GRIA2; MAOA; GRIA4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.251E-03 | 1.627E-02 | PTPN1; CSNK2A1; MAPK1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.810E-03 | 1.114E-02 | GSK3B; MAPK1; TP53 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 3.311E-03 | 1.015E-02 | AKR1B10; AKR1B1; GLA |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.152E-04 | 1.972E-03 | MAPK1; PPARG; TP53 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.424E-03 | 5.419E-03 | ABCC1; CFTR; ABCG2 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 6.109E-04 | 2.523E-03 | POLB; PARP1; APEX1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.450E-02 | 4.952E-02 | PKM; MAPK1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.262E-02 | 4.672E-02 | CYP3A4; XDH |
| hsa05033 | Nicotine addiction_Homo sapiens_hsa05033 | 1.739E-02 | 3.670E-02 | GRIA2; GRIA4 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 1.822E-02 | 3.804E-02 | FABP2; PLA2G1B |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.739E-02 | 3.670E-02 | PKM; GLO1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.135E-02 | 2.764E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.423E-02 | 3.297E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.962E-03 | 1.573E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.500E-04 | 1.357E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; GRM5; GRM2; PPARD |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; CD38; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Fragile X syndrome | F02.3, G20, Q99.2 | GRM5 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; TERT; PARP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Chronic neuropathic pain | G64, G90.0, K21, R52, G89 | GRM5; GRM5 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; GRIK1; GRM1; ACHE; PTGS2; PTGS2; PTGS2; PTGS2; FAAH; ESR1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B; ALOX5; SYK; MMP12; PTGS2; FAAH |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; FLT3; TERT; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ALOX5; SYK; PTGS2; PTGS2; PTGS2; PTGS2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRIK1; GRM1; GRM5; GRM4; ESR1; APP |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | GRM2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; GRM3; GRM2 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; MMP9; TP53 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; GRM5; GRM2 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE; FAAH; GRM5; GRM3; GRM2; GRM4; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; GRM1; ACHE; ACHE; ACHE; PTGS2; GSK3B; PPARG; PPARG; GRM5; GRM3; GRM2; APP |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; GRIK1; GRM1; PTGS2; PTGS2; GRM5 |
| NA: NA | GERD | NA | GRM5 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| NA: NA | Dyslipidemia | NA | PPARD |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; GRIK1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TLR2; PKM; SYK; FLT3; MMP2; HIF1A; MAPK1; MMP9; TP53 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PTGS2; NFKB1; PPARG; PPARG; GPBAR1; PPARD |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; GRIK1; GRIK1 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TERT; TP53; TP53 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; PTPN1; GSK3B; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; GRIA4; GRIA2; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; FLT3; MMP2; PTGS2; TERT |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | GRM2 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; GRM5 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Autism | F84.0 | GRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; SYK; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2; ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; TERT; CYP19A1; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12; PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38; TERT |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; TLR2; CSNK2A1; SYK; FLT3; FLT3; MMP2; ACHE; PTGS2; CD38; GSK3B; ADORA3; HIF1A; MAPK1; MMP9; NFKB1; PIM1; PARP1; CDC25B; TP53; ESR1; ESR1; APP |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; PARP1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARG; PPARD; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADORA3 |
| NA: NA | GIST | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH; GRM5; GRM5; GRM3; GRM2; GRM2 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |